27312379|t|Evaluation of the in vitro growth of urinary tract infection -causing gram-negative and gram-positive bacteria in a proposed synthetic human urine (SHU) medium
27312379|a|Bacteriuria is a hallmark of urinary tract infection (UTI) and asymptomatic bacteriuria (ABU), which are among the most frequent infections in humans. A variety of gram-negative and gram-positive bacteria are associated with these infections but Escherichia coli contributes up to 80% of cases. Multiple bacterial species including E. coli can grow in human urine as a means to maintain colonization during infections. In vitro bacteriuria studies aimed at modeling microbial growth in urine have utilized various compositions of synthetic human urine (SHU) and a Composite SHU formulation was recently proposed. In this study, we sought to validate the recently proposed Composite SHU as a medium that supports the growth of several bacterial species that are known to grow in normal human urine and/or artificial urine. Comparative growth assays of gram-negative and gram-positive bacteria E. coli, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus agalactiae, Staphylococcus saprophyticus and Enterococcus faecalis were undertaken using viable bacterial count and optical density measurements over a 48h culture period. Three different SHU formulations were tested in various culture vessels, shaking conditions and volumes and showed that Composite SHU can support the robust growth of gram-negative bacteria but requires supplementation with 0.2% yeast extract to support the growth of gram-positive bacteria. Experiments are also presented that show an unexpected but major influence of P. mirabilis towards the ability to measure bacterial growth in generally accepted multiwell assays using absorbance readings, predicted to have a basis in the release of volatile organic compound(s) from P. mirabilis during growth in Composite SHU medium. This study represents an essential methodological validation of a more chemically defined type of synthetic urine that can be applied to study mechanisms of bacteriuria and we conclude will offer a useful in vitro model to investigate the basis of some of the most common infections of humans.
27312379	0	10	Evaluation	T058	C0220825
27312379	18	26	in vitro	T080	C1533691
27312379	27	33	growth	T040	C0178747
27312379	37	60	urinary tract infection	T047	C0042029
27312379	70	83	gram-negative	T007	C0018150
27312379	88	110	gram-positive bacteria	T007	C0018154
27312379	116	124	proposed	T080	C1553874
27312379	125	134	synthetic	T080	C2004457
27312379	135	140	human	T016	C0086418
27312379	141	146	urine	T031	C1610733
27312379	148	151	SHU	T031	C1610733
27312379	153	159	medium	T130	C0010454
27312379	160	171	Bacteriuria	T047	C0004659
27312379	189	212	urinary tract infection	T047	C0042029
27312379	214	217	UTI	T047	C0042029
27312379	223	247	asymptomatic bacteriuria	T047	C0262380
27312379	249	252	ABU	T047	C0262380
27312379	280	288	frequent	T079	C0332183
27312379	289	299	infections	T046	C3714514
27312379	303	309	humans	T016	C0086418
27312379	324	337	gram-negative	T007	C0018150
27312379	342	364	gram-positive bacteria	T007	C0018154
27312379	369	384	associated with	T080	C0332281
27312379	391	401	infections	T046	C3714514
27312379	406	422	Escherichia coli	T007	C0014834
27312379	423	434	contributes	T052	C1880177
27312379	448	453	cases	T077	C1706256
27312379	455	463	Multiple	T081	C0439064
27312379	464	481	bacterial species	T007	C0004611
27312379	492	499	E. coli	T007	C0014834
27312379	504	508	grow	T040	C0178747
27312379	512	517	human	T016	C0086418
27312379	518	523	urine	T031	C1610733
27312379	538	546	maintain	T052	C0024501
27312379	547	559	colonization	T033	C4289767
27312379	567	577	infections	T046	C3714514
27312379	579	587	In vitro	T080	C1533691
27312379	588	599	bacteriuria	T047	C0004659
27312379	600	607	studies	T062	C2603343
27312379	608	613	aimed	T078	C1947946
27312379	617	625	modeling	T062	C0870071
27312379	626	642	microbial growth	T040	C0178747
27312379	646	651	urine	T031	C1610733
27312379	674	686	compositions	T201	C0486616
27312379	690	699	synthetic	T080	C2004457
27312379	700	705	human	T016	C0086418
27312379	706	711	urine	T031	C1610733
27312379	713	716	SHU	T031	C1610733
27312379	724	733	Composite	T080	C0205199
27312379	734	737	SHU	T031	C1610733
27312379	738	749	formulation	T167	C0729650
27312379	763	771	proposed	T080	C1553874
27312379	781	786	study	T062	C2603343
27312379	801	809	validate	T062	C1519941
27312379	823	831	proposed	T080	C1553874
27312379	832	841	Composite	T080	C0205199
27312379	842	845	SHU	T031	C1610733
27312379	851	857	medium	T130	C0010454
27312379	863	871	supports	T077	C1521721
27312379	876	882	growth	T040	C0178747
27312379	886	893	several	T081	C0443302
27312379	894	911	bacterial species	T007	C0004611
27312379	930	934	grow	T040	C0178747
27312379	938	944	normal	T080	C0205307
27312379	945	950	human	T016	C0086418
27312379	951	956	urine	T031	C1610733
27312379	964	974	artificial	T080	C2004457
27312379	975	980	urine	T031	C1610733
27312379	982	993	Comparative	T062	C0683941
27312379	994	1007	growth assays	T034	C0427944
27312379	1011	1024	gram-negative	T007	C0018150
27312379	1029	1051	gram-positive bacteria	T007	C0018154
27312379	1052	1059	E. coli	T007	C0014834
27312379	1061	1083	Pseudomonas aeruginosa	T007	C0033809
27312379	1085	1102	Proteus mirabilis	T007	C0033701
27312379	1104	1128	Streptococcus agalactiae	T007	C0579233
27312379	1130	1158	Staphylococcus saprophyticus	T007	C0318112
27312379	1163	1184	Enterococcus faecalis	T007	C0038404
27312379	1207	1213	viable	T080	C0443348
27312379	1214	1229	bacterial count	T059	C0004618
27312379	1234	1262	optical density measurements	T059	C1266211
27312379	1274	1281	culture	T059	C0430400
27312379	1282	1288	period	T079	C1948053
27312379	1306	1309	SHU	T031	C1610733
27312379	1310	1322	formulations	T167	C0729650
27312379	1328	1334	tested	T169	C0039593
27312379	1338	1345	various	T080	C1705242
27312379	1346	1361	culture vessels	T074	C3856437
27312379	1363	1381	shaking conditions	T052	C1883023
27312379	1386	1393	volumes	T081	C0449468
27312379	1410	1419	Composite	T080	C0205199
27312379	1420	1423	SHU	T031	C1610733
27312379	1428	1435	support	T077	C1521721
27312379	1440	1446	robust	T080	C2986815
27312379	1447	1453	growth	T040	C0178747
27312379	1457	1479	gram-negative bacteria	T007	C0018150
27312379	1484	1492	requires	T080	C0027552
27312379	1493	1508	supplementation	T169	C2348609
27312379	1519	1532	yeast extract	T004	C1960916
27312379	1536	1543	support	T077	C1521721
27312379	1548	1554	growth	T040	C0178747
27312379	1558	1580	gram-positive bacteria	T007	C0018154
27312379	1582	1593	Experiments	T062	C0681814
27312379	1626	1636	unexpected	T170	C4055646
27312379	1641	1646	major	T080	C0205164
27312379	1647	1656	influence	T077	C4054723
27312379	1660	1672	P. mirabilis	T007	C0033701
27312379	1696	1720	measure bacterial growth	T034	C0427944
27312379	1724	1742	generally accepted	T080	C1272684
27312379	1743	1759	multiwell assays	T059	C1510438
27312379	1766	1785	absorbance readings	T201	C1268822
27312379	1787	1796	predicted	T078	C0681842
27312379	1807	1812	basis	T169	C1527178
27312379	1820	1827	release	T169	C1283071
27312379	1831	1859	volatile organic compound(s)	T109	C2350439
27312379	1865	1877	P. mirabilis	T007	C0033701
27312379	1885	1891	growth	T040	C0178747
27312379	1895	1904	Composite	T080	C0205199
27312379	1905	1908	SHU	T031	C1610733
27312379	1909	1915	medium	T130	C0010454
27312379	1922	1927	study	T062	C2603343
27312379	1942	1951	essential	T080	C0205224
27312379	1952	1966	methodological	T170	C0969625
27312379	1967	1977	validation	T062	C1519941
27312379	1983	1987	more	T081	C0205172
27312379	1988	1998	chemically	T103	C0220806
27312379	1999	2006	defined	T052	C1880022
27312379	2015	2024	synthetic	T080	C2004457
27312379	2025	2030	urine	T031	C1610733
27312379	2054	2059	study	T062	C2603343
27312379	2060	2070	mechanisms	T169	C0441712
27312379	2074	2085	bacteriuria	T047	C0004659
27312379	2093	2101	conclude	T078	C1707478
27312379	2122	2136	in vitro model	T062	C0681828
27312379	2140	2151	investigate	T169	C1292732
27312379	2156	2161	basis	T169	C1527178
27312379	2189	2199	infections	T046	C3714514
27312379	2203	2209	humans	T016	C0086418